Darigabat - Cerevel Therapeutics
Alternative Names: CVL-865; PF-06372865; PF-6372865Latest Information Update: 03 Jun 2024
At a glance
- Originator Pfizer
- Developer Cerevel Therapeutics; Pfizer
- Class Analgesics; Antiepileptic drugs; Anxiolytics; Fluorobenzenes; Heterocyclic compounds; Imidazoles; Phenyl ethers; Pyrazines; Small molecules; Sulfones
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Epilepsy; Panic disorder; Seizures
- Preclinical Anxiety disorders
- Discontinued Back pain; Generalised anxiety disorder
Most Recent Events
- 30 May 2024 Cerevel Therapeutics plans a phase I pharmacokinetics trial for Neurological disorders (In Volunteers) in the US (PO, capsule) (NCT06435923)
- 29 May 2024 Cerevel Therapeutics initiates a phase I trial in healthy volunteers in USA (PO) (NCT06435923)
- 21 May 2024 Cerevel Therapeutics completes the phase II trial in Seizures (Adjunctive treatment, In the elderly, Treatment-resistant, In adults) in Ukraine (PO) (NCT04244175)